Постинсультные когнитивные нарушения и деменция

Д. В. Сергеев; М. А. Домашенко; М. А. Пирадов

doi:10.21518/2079-701X-2016-8-34-37

Постинсультные когнитивные нарушения и деменция

Д. В. Сергеев, М. А. Домашенко, М. А. Пирадов

https://doi.org/10.21518/2079-701X-2016-8-34-37

Полный текст:

PDF (Rus)

Аннотация

В обзоре, подготовленном по данным последних публикаций ведущих европейских специалистов в области постинсультных когнитивных нарушений, приведены краткие сведения о распространенности, механизмах развития и факторах риска этих состояний, которые представляют собой серьезную проблему в период восстановления после инсульта. Описаны общие подходы к профилактике постинсультной деменции и возможности нейропротективной терапии у этой категории пациентов.

Ключевые слова

постинсультные когнитивные нарушения, деменция, нейропротекторы, цитиколин, post stroke cognitive impairment, dementia, neuroprotective agents, citicoline, post stroke cognitive impairment, dementia, neuroprotective agents, citicoline

Об авторах

Д. В. Сергеев

Научный центр неврологии
Россия

М. А. Домашенко

Научный центр неврологии
Россия

М. А. Пирадов

Научный центр неврологии
Россия

Список литературы

1. Пирадов М.А., Танашян М.М., Домашенко М.А., Сергеев Д.В., Максимова М.Ю. Нейропротекция при цереброваскулярных заболеваниях: поиск жизни на марсе или перспективное направление лечения? Часть 1. Острые нарушения мозгового кровообращения. Анналы клинической и экспериментальной неврологии, 2015, 9(1): 41-50.

2. Alvarez-Sabin J, Ortega G, Jacas C et al: Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. CerebrovascDis, 2013, 35: 146-54.

3. Alvarez-Sabin J, Santamarina E, Maisterra O et al. Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke. 7nt J Mol Sci, 2016, 17(3): 390.

4. Ankolekar S, Geeganage C, Anderton P, Hogg C, Bath PMW. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci, 2010, 299: 168-174

5. Brainin M, Tuomilehto J, Heiss WD, Bornstein NM, Bath PM, Teuschl Y, Richard E, Guekht A, Quinn T; Post Stroke Cognition Study Group. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur J Neurol, 2015, 22(2): 229-38, e13-6.

6. D. Leys, H. Henon, M.A. Mackowiak-Cordoliani, F. Pasquier, Poststroke dementia. Lancet Neurol, 2005, 4: 752-759.

7. Davalos A, Alvarez-Sabin J, Castillo J et al., International Citicoline Trial on Acute Stroke (ICTUS) trial investigators: Citicoline in the treatment of acute ischemic stroke: an international, randomized, multicentre, placebocontrolled study (ICTUS trial). Lancet, 2012, 380: 349-5.

8. Dhamoon MS, Moon YP, Paik MC, Boden Albala B, Rundek T, Sacco RL, Elkind MS. Quality of life declines after first ischemic stroke. The Northern Manhattan Study. Neurology, 2010, 75: 328-334.

9. Panza F, Solfrizzi V, Logroscino G, Maggi S, Santa-mato A, Seripa D, Pilotto A. Current epidemiological approaches to the metabolic-cognitive syndrome. J. Alzheimers Dis., 2012, 30(Suppl. 2): S31-S75.

10. Fioravanti M, Yanagi M: Cytidinediphospho-choline (CDP-choline) for cognitive and behavioral disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev, 2005, 2: CD000269.

11. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop, Neurology, 1993, 43: 250-260.

12. Gaugler JE, Kane RL, Kane RA, Clay T, Newcomer R. Caregiving and institutionaliza-tion of cognitively impaired older people: Utilizing dynamic predictors of change. Gerontologist, 2003, 43: 219-229.

13. Jokinen H, Melkas S, Ylikoski R, Pohjasvaara T, Kaste M, Erkinjuntti T, Hietanen M. Post-stroke cognitive impairment is common even after successful clinical recovery. European Journal of Neurology, 2015, 22: 1288-1294.

14. Markus HS, Bevan S. Mechanisms and treatment of ischaemic stroke-insights from genetic associations. Nat Rev. Neurol., 2014, 10: 723-730.

15. Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, Chui HC. Neuropathology substrates of ischemic vascular dementia. J. Neuropathol. Exp. Neurol., 2000, 59: 931-945.

16. Hughes JL, Beech JS, Jones PS, Wang D, Menon DK, Baron JC. Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat. NeuroImage, 2010, 49: 19-31.

17. Yang J, Wong A, Wang Z, Liu W, Au L, Xiong Y, Chu WW, Leung EY, Chen S, Lau C, Chan AY, Lau AY, Fan F, Ip V, Soo Y, Leung T, Ho CL, Wong LK, Mok VC. Risk factors for incident dementia after stroke and transient ischemic attack. Alzheimers Dement., 2014.

18. Jacquin A, Aboa-Eboule C, Rouaud O et al. Prior transient ischemic attack and dementia after subsequent ischemic stroke. Alzheimer Dis. Assoc. Disord., 2012, 26: 307-313.

19. Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta, 2016, 1862(5): 915-25.

20. Kennedy EP: Sailing to Byzantium. Annu Rev Biochem, 1992, 61: 1-28.

21. Allan LM, Rowan EN, Firbank MJ, Thomas AJ, Parry SW, Polvikoski TM, O'Brien JT, Kalaria RN. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain J. Neurol., 2012,134: 3716-3727,

22. Lin JH, Lin RT, Tai CT et al. Prediction of post-stroke dementia. Neurology, 2003, 61: 343-348.

23. Duering M, Csanadi E, Gesierich B, Jouvent E, Herve D, Seiler S, Belaroussi B, Ropele S, Schmidt R, Chabriat H, Dichgans M. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain J. Neurol., 2013, 136: 2717-2726.

24. Ihara M, Polvikoski TM, Hall R, Slade JY, Perry RH, Oakley AE, Englund E, O'Brien JT, Ince PG, Kalaria RN. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol., 2010, 119: 579-589.

25. Prencipe M, Ferretti C, Casini AR, Santini M, Giubilei F, Culasso F. Stroke, disability, and dementia: results of a population survey. Stroke, 1997, 28: 531-536.

26. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury, Stroke 2006, 37: 1391-1398.

27. McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, Yurgelun-Todd D. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. JAtten Disord., 2015.

28. McGlade E et al. Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences, 2012, 3: 769-773.

29. Kandiah N, Wiryasaputra L, Narasimhalu K, Karandikar A, Marmin M, Chua EV, Sitoh YY. Frontal subcortical ischemia is crucial for post stroke cognitive impairment. J. Neurol. Sci., 2011, 309: 92-95.

30. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology, 2009, 72: 56-62.

31. Osman AM, Porritt MJ, Nilsson M, Kuhn HG. Long-term stimulation of neural progenitor cell migration after cortical ischemia in mice. Stroke, 2011, 42: 3559-3565.

32. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet, 2004, 363: 1925-1933.

33. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T. Poststroke dementia: clinical features and risk factors. Stroke, 2000, 31: 1494-1501.

34. Vataja R, Pohjasvaara T, Mantyla R, Ylikoski R, Leppavuori A, Leskela M, Kalska H, Hietanen M, Aronen HJ, Salonen O, Kaste M, Erkinjuntti T. MRI correlates of executive dysfunction in patients with ischaemic stroke. Eur. J. Neurol., 2003, 10: 625-631.

35. Kalaria RN, Ihara M. Dementia: vascular and neurodegenerative pathways-will they meet? Nat. Rev. Neurol., 2013, 9: 487-488.

36. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuro-pathological substrates of vascular dementia. J. Neurol. Sci., 2004, 226: 75-80.

37. Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr. Alzheimer Res., 2013, 10: 642-653.

38. Richard E, Andrieu S, Solomon A, et al. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI). J Neurol Sci, 2012, 322: 64-70.

39. Royall DR, Lauterbach EC, Kaufer D, Malloy P, Coburn KL, Black KJ. The cognitive correlates of functional status: A review from the Committee on Research of the American Neuropsychiatric Association. J. Neuropsychiatr. Clin. Neurosci, 2007, 19: 249-265.

40. Stephens S, Kenny RA, Rowan E, Allan L, Kalaria RN, Bradbury M, Ballard CG. Neuropsychological characteristics of mild vascular cognitive impairment and dementia after stroke. Int. J. Geriatr. Psychiatry, 2004, 19: 1053-1057.

41. S.T Pendlebury, PM. Rothwell, Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis, Lancet Neurol. 8 (2009) 1006-1018.

42. Pendlebury ST. Stroke-related dementia: rates, risk factors and implications for future research. Maturitas, 2009, 64: 165-171.

43. Schmidt R, Ropele S, Ferro J, et al. Diffusion-weighted imaging and cognition in the leu-koariosis and disability in the elderly study. Stroke, 2010, 41: e402-e408.

44. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med., 2014, 2(8): 80.

45. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of poststroke dementia. Stroke, 1998, 29: 75-81.

46. Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano M, Remien RH, Williams JB, Mohr JP Hauser WA et al., Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology, 1992, 42: 1185-1193.

47. Polvikoski TM, van Straaten EC, Barkhof F, Sulkava R, Aronen HJ, Niinisto L, Oinas M, Scheltens P Erkinjuntti T, Kalaria RN. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology, 2010, 75: 2071-2078.

48. Tzourio C, Anderson C, Chapman N., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med, 2003, 163: 1069-1075.

49. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke, 2006, 37: 2220-2241.

50. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol, 2009, 8: 355-369.

51. Wardlaw JM, Smith EE, Biessels GJ et al. Neuro-imaging standards for research into small vessel disease and its contribution to ageing and neuro-degeneration. Lancet Neurol, 2013, 12: 822-838.

52. Teuschl Y, Matz K, Brainin M. Prevention of post-stroke cognitive decline: a review focusing on lifestyle interventions. Eur. J. Neurol., 2013, 20: 35-49.

53. Yamamoto Y, Craggs L, Baumann M, Kalimo H, Kalaria RN. Review: molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol. Appl. Neurobiol. 2011, 37: 94-113.

54. Zafonte RD, Bagiella E, Ansel BM et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA, 2012, 308: 1993-2000.54.